EANS-Adhoc: - The Marseille-Kliniken Group focuses on its core competency - nursing care - Revenues increased in the first three quarters of 2009/2010 by 6.3% to EUR 186.1 million - EBIT/IFRS rose t

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

quarterly report

10.05.2010

Berlin, 10 May 2010. The Marseille-Kliniken Group (Prime Standard,
ISIN DE 0007783003, MKA) increased its operating sales by 6.3% to EUR
186.1 million (previous year: EUR 175.1 million) in the first nine
months of the 2009/2010 financial year (1 July 2009 - 31 March 2010).
EBITDAR/IFRS increased from EUR 43.1 million to EUR 47.1 million.
EBIT/IFRS amounted to EUR 3.9 million compared to EUR 1.4 million in
the previous year. Net profit before minority interests amounted to
EUR -1.3 million in the period under review. This corresponds to an
increase of EUR 1.8 million compared to EUR -3.1 million in the
previous year. Earnings per share therefore rose to EUR -0.12
(previous year: EUR -0.25). Shareholders´ equity dropped from EUR
74.7 million to EUR 60.1 million and the equity ratio fell from 33.3%
to 27.3% as a result. Financial debt decreased from EUR 68.7 million
to EUR 61.1 million. Marseille-Kliniken Group evaluates these figures
as a proof of constantly positive effects due to the intensive
activities in sales and cost optimizing.

With 322 beds being added, the occupancy rate remained almost at the
same high level as in the previous year. The 9,417 beds held by the
Group accounted for an occupancy rate of 92.4% (previous year: 92.5%;
9,085 beds). As from the end of the period under review, the
Marseille-Kliniken Group will no longer adjust selected profit
figures in accordance with DVFA/SG (IFRS). This measure aims at
increasing the transparency of the accounting measures.

The care division increased its capacity from 7,756 to 8,088 beds as
of the balance sheet date, making it solely responsible for the
Group's rise in capacity. Beds were added at the facilities in
Bremerhaven, Oberhausen and Waldkirch. Segment revenues increased
from EUR 134.6 million in the previous year to EUR 142.7 million,
mainly due to higher sales from these three facilities. Earnings
after taxes and before minority interests of EUR -1.0 million
(previous year: EUR -2.1 million) were negatively affected by
start-up losses for new facilities of EUR 5.7 million (previous
year: EUR 5.4 million). The sale of a property in Bremerhaven
amounting to EUR 1.6 million, on the other hand, had a positive
effect. The occupancy rate at continually existing care facilities
was 92.1% compared to 92.4% in the previous year.

Capacity of the rehabilitation division remained unchanged
year-on-year at 1,329 beds. The division´s revenues rose from EUR
40.5 million in the previous year to EUR 43.3 million. Earnings after
taxes and before minority interests increased from EUR -0.9 million
to EUR -0.3 million. The segment´s occupancy rate rose from 92.7% to
94.3%.

In the fourth quarter of the current financial year, the
Marseille-Kliniken Group disposed of all its rehabilitation clinics.
The respective subsidiaries were deconsolidated as of 30 April 2010
and are therefore of no further relevance to future planning.
Revenues generated by this sale are being used for developing and
expanding the Group´s core division - care.

Marseille-Kliniken Group has introduced regional managers, who are to
increase occupancy rates, and therefore revenues, in seven regions in
order to improve its core competency nursing care. Special attention
is being paid to those facilities with the largest potential for
improvement. In order to increase profitability as well, various
optimisation programmes have been implemented to reduce personnel
costs and cost of materials without compromising the Group's high
quality standards. As a consequence, the Marseille-Kliniken Group
anticipates positive earnings in the current financial year.

For more detailed information please refer to the quarterly report,
which is being published today on our website at
www.marseille-kliniken.com.

End of ad hoc release

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Hillermann Consulting

Christian Hillermann

Investor Relations for Marseille-Kliniken AG

Poststraße 14/16

20354 Hamburg

Germany

Tel.: +49 (0)40 / 320 279-10

Fax: +49 (0)40 / 320 279-114

www.hillermann-consulting.de

Marseille-Kliniken AG

Dr. Ute Buchheim

Friedrich-Ebert-Str. 65

33330 Gütersloh

Germany

Tel.: +49 (0)5241 / 90 39-35

Fax: +49 (0)5241 / 90 39-39

www.marseille-kliniken.com

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hamburg / regulated dealing